Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone-Reference-Cited by-同舟云学术

Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone

Published:2019-10 Issue:10 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Arca-Suárez Jorge¹²,Fraile-Ribot Pablo³⁴,Vázquez-Ucha Juan Carlos¹,Cabot Gabriel³⁴^ORCID,Martínez-Guitián Marta¹,Lence Emilio⁵⁶,González-Bello Concepción⁵⁶,Beceiro Alejandro¹,Rodríguez-Iglesias Manuel²⁷,Galán-Sánchez Fátima²⁷,Bou Germán¹,Oliver Antonio³⁴^ORCID

Affiliation:

1. Servicio de Microbiología-Instituto de Investigación Biomédica, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain

2. Servicio de Microbiología, Hospital Universitario Puerta del Mar, Instituto de Investigación e Innovación Biomédica de Cádiz, Cádiz, Spain

3. Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears, Palma de Mallorca, Spain

4. Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears, Palma de Mallorca, Spain

5. Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares, Universidade de Santiago de Compostela, Santiago de Compostela, Spain

6. Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain

7. Departamento de Microbiología, Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain

Abstract

Selection of extended-spectrum mutations in narrow-spectrum oxacillinases (e.g., OXA-2 and OXA-10) is an emerging mechanism for development of in vivo resistance to ceftolozane-tazobactam and ceftazidime-avibactam in Pseudomonas aeruginosa . Detection of these challenging enzymes therefore seems essential to prevent clinical failure, but the complex phenotypic plasticity exhibited by this species may often lead to their underestimation.

Funder

Xunta de Galicia

Ministerio de Economía, Industria y Competitividad, Gobierno de España

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01110-19

Reference28 articles.

1. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

2. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa